Team:Stony Brook
Colon cancer is the second leading cause of cancer death in the United States. Each year, almost 140,000 people are diagnosed with colon cancer, and 50,000 people die from the disease1. Diagnosis and treatment often require invasive procedures, including colonoscopies and surgery. Less invasive treatments such as chemotherapy cause unpleasant side effects. We turn to synthetic biology to develop a better colon cancer therapy. An ideal cell-based therapy would have two significant components: a way to kill cancer cells, and a way to specifically target them. In our quest to find a way to specifically target cancer cells, we found that the problem of controlling a cell’s interaction with its physical environment extended beyond cancer therapy into a myriad of biological contexts. Harvard iGEM 2015 focuses on building a platform for controlling specific bacterial adhesion in a variety of biological settings, including colon cancer therapy.
Learn what we are all about. Here you can learn how we set up and conducted our research.
Find our major accomplishments here and where we plan to go with them.
The story of our hard work.
View the parts we created.
A guide to how to take research to the next level.
Safety is what really matters.
Outreach to our fellow iGEMers.
See who participated on this year’s iGEM team.
